We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker Launches MAKO Robotic-Arm for Knee Anthroplasty
Read MoreHide Full Article
Kalamazoo, MI-based medical technology company, Stryker Corporation (SYK - Free Report) recently announced the commercial launch of a robotic-arm assisted total knee arthroplasty application based on its flagship MAKO System.
The MAKO robotic-arm technology will help surgeons carry out medical processes seamlessly. Stryker launched the technology at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego.
Per management, the latest development marks the first and only robotic technology, which can be used during the joint replacement service while performing total knee, total hip and partial knee replacements.
Stock Performance
The price performance of Stryker has been encouraging of late. Over the last one year, the stock added 24.5%, higher than the Zacks classified Medical Product sub-industry’s gain of roughly 10.7%. Furthermore, the current return of the stock is higher than the S&P 500’s 16.4% over the same time frame.
The estimate revision trend for the stock has been dismal with one estimate moving south in the last seven days compared to no movement in the opposite direction. Notably, the current year estimate for the stock stands at $6.41. Stryker has a Zacks Rank #3 (Hold).
Bottom Line
Per management, total knee replacements in the U.S. are expected to shoot up 673% by 2030. Stryker’s top line in the last reported quarter gained significantly on the MAKO platform with almost 32 global installations of robots, of which 24 were in the U.S. For full-year 2016, MAKO installations were 86, implying an increase of 14 robots on a year-over-year basis.
Stryker has a diversified product portfolio. Its wide range of products cushions the company against any significant sales shortfall during economic downturns. Stryker’s pipeline includes products like Hip, Knee and Mako Robotic-Arm assisted surgeries.
Inogen has a long-term expected earnings growth rate of 17.05%. Notably, the stock represents an impressive one-year return of 77.4%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock has added 6.08% over the last one year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Stryker Launches MAKO Robotic-Arm for Knee Anthroplasty
Kalamazoo, MI-based medical technology company, Stryker Corporation (SYK - Free Report) recently announced the commercial launch of a robotic-arm assisted total knee arthroplasty application based on its flagship MAKO System.
The MAKO robotic-arm technology will help surgeons carry out medical processes seamlessly. Stryker launched the technology at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego.
Per management, the latest development marks the first and only robotic technology, which can be used during the joint replacement service while performing total knee, total hip and partial knee replacements.
Stock Performance
The price performance of Stryker has been encouraging of late. Over the last one year, the stock added 24.5%, higher than the Zacks classified Medical Product sub-industry’s gain of roughly 10.7%. Furthermore, the current return of the stock is higher than the S&P 500’s 16.4% over the same time frame.
The estimate revision trend for the stock has been dismal with one estimate moving south in the last seven days compared to no movement in the opposite direction. Notably, the current year estimate for the stock stands at $6.41. Stryker has a Zacks Rank #3 (Hold).
Bottom Line
Per management, total knee replacements in the U.S. are expected to shoot up 673% by 2030. Stryker’s top line in the last reported quarter gained significantly on the MAKO platform with almost 32 global installations of robots, of which 24 were in the U.S. For full-year 2016, MAKO installations were 86, implying an increase of 14 robots on a year-over-year basis.
Stryker Corporation Price
Stryker Corporation Price | Stryker Corporation Quote
Stryker has a diversified product portfolio. Its wide range of products cushions the company against any significant sales shortfall during economic downturns. Stryker’s pipeline includes products like Hip, Knee and Mako Robotic-Arm assisted surgeries.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, Inogen sports a Zacks Rank #1 (Strong Buy) while Fluidigm and Avinger carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.05%. Notably, the stock represents an impressive one-year return of 77.4%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock has added 6.08% over the last one year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think. See This Ticker Free >>